• Profile
Close

Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab

Journal of the American Academy of Dermatology Sep 21, 2017

Albers LN, et al. - This study was executed in order to determine the biomarkers to speculate the relapse of pemphigus following rituximab therapy. It was deduced that a correlation existed between the relapse with B-cell repopulation, low CD4+ T -cell count, and positive result of testing for desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3).

Methods

  • Longitudinal clinical scoring and biomarker data was obtained from 62 patients with pemphigus, treated with 99 rituximab cycles.
  • It including levels of CD19+ B cells, CD4+ T cells, and desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3) autoantibodies.
  • The extended time-variant Kaplan-Meier estimator and extended Cox model werew applied

Results

  • Rare relapse was found before B-cell repopulation.
  • Univariate analysis exhibited low CD4 count (<400 cells/μL) to predict relapse (P < .001).
  • A positive result of testing for Dsg1 (>20 IU) speculated the relapse among patients with mucocutaneous disease (hazard ratio, 6.40; P = .019).
  • A positive result of testing for Dsg3 (>20 IU) appeared to be predictive in patients with mucocutaneous and mucosal disease (hazard ratio, 32.92; P < .001).
  • It was determined that CD4 value increase of 200 caused a decrease in the hazard ratio for relapse by 35% (P = .029), unveiled by the multivariable analysis.
  • A positive result of testing for Dsg1 increased the risk for relapse by a factor of 12.32 in patients with mucocutaneous disease (P = .001).
  • Positive result of testing for Dsg3 raised the risk for relapse by 28.38 in patients with mucosal and mucocutaneous disease (P = .006).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay